logo
A complete guide to weight loss using anti-obesity GLP-1 medications

A complete guide to weight loss using anti-obesity GLP-1 medications

India Today5 days ago
With the launch of popular GLP-1 weight loss medications like Wegovy (semaglutide) and Mounjaro (tirzepatide) in India, interest in medical weight loss is booming.But while these drugs have shown dramatic results by helping people shed 15–21% of their body weight, experts caution that relying solely on medication could come at a cost.A new publication by doctors from Mass General Brigham, the largest hospital-based research enterprise in the US and affiliated to Harvard Medical School, shows how a structured nutrition and exercise plan can aid long-term success, avoid muscle loss, and reduce unpleasant side effects.advertisement
THE MISSING LINK: MUSCLE AND MEALSWhile GLP-1 drugs work by suppressing appetite, slowing digestion, and increasing fullness, they can also cause loss of lean muscle mass, not just fat. This makes protein intake and muscle maintenance essential.The guidance advises patients to begin each meal with 20–30 grams of protein from sources such as fish, tofu, chickpeas, or eggs.A daily goal of 1 to 1.5 grams of protein per kilogram of body weight is recommended for those who are moderately active. For patients with very low appetite, protein shakes with at least 20 grams per serving may help.To avoid energy crashes, smaller meals with healthy snacks like fruits, nuts, or unsweetened yogurt are recommended.
(Credit: Harvard Medical School)
Slow-digesting carbohydrates such as sweet potatoes and oatmeal are preferred over refined grains and sugary foods.Healthy fats like olive oil and avocado can also help improve satiety and nutrient absorption.SIDE EFFECT MANAGEMENT STARTS IN THE KITCHENGLP-1 medications are known to cause digestive side effects, including nausea, heartburn, and constipation. The publication outlines clear, practical tips to minimise discomfort:For nausea, avoid high-fat or greasy foods. Choose bland options like whole-grain toast and try ginger tea or fruit.For heartburn, eat smaller portions and avoid lying down for 2–3 hours after meals.For constipation, increase both soluble and insoluble fibre (from oats, apples, vegetable skins, nuts), paired with plenty of water.Aim for 2–3 litres of fluid daily, primarily water, along with hydrating foods like watermelon, soups, and cucumbers.Importantly, extreme calorie restriction while on GLP-1 medications is discouraged, as it may worsen fatigue, dehydration, and nutrient deficiencies.The authors also advise caution with highly restrictive diets, including strict vegan plans that may lack vitamin B12, iron, and protein.WHY EXERCISE STILL MATTERSAlthough GLP-1 drugs reduce hunger and promote weight loss, physical activity remains key to sustaining results and maintaining health. The authors recommend a three-step exercise plan:Start slow: Begin with 10 minutes of brisk walking or other moderate activity per day and build up to 150 minutes per week.Add resistance: Strength training (e.g., squats, lunges, bands, or weights) should be done 2–3 times weekly for 30 minutes.Maintain it: Continue with 30–60 minutes of daily activity, alongside regular strength training.advertisementThis structured routine helps patients retain muscle mass and improve overall well-being, something medication alone cannot do.The guidance also includes practical tools like food tracking (through apps, photos, or diaries), and encourages continued lifestyle changes even if the medication is stopped, as this helps prevent weight regain.- EndsMust Watch
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sun Pharma's ILUMYA delivers positive psoriatic arthritis trial results
Sun Pharma's ILUMYA delivers positive psoriatic arthritis trial results

Business Standard

timean hour ago

  • Business Standard

Sun Pharma's ILUMYA delivers positive psoriatic arthritis trial results

Sun Pharmaceutical Industries has announced that its psoriasis drug ILUMYA (tildrakizumab 100 mg) delivered positive results in two late-stage clinical trials for active psoriatic arthritis (PsA), potentially paving the way for regulatory filings in the United States. The Phase 3 INSPIRE-1 and INSPIRE-2 studies evaluated the efficacy and safety of ILUMYA over a 24-week period. According to the company, both trials achieved statistically significant improvements in ACR20 response rates—a standard measure of arthritis treatment effectiveness—compared with placebo at Week 24. INSPIRE-1 included patients with prior exposure to anti-TNF therapies, while INSPIRE-2 focused on anti-TNF naïve patients. More than 800 adult participants were enrolled across clinical sites in the US, Europe, and Asia. ILUMYA was administered at Week 0 and every 12 weeks thereafter, with no induction dose. Consistent safety profile supports regulatory case Sun Pharma stated that the safety outcomes in the psoriatic arthritis trials were consistent with ILUMYA's established safety profile from earlier studies in plaque psoriasis. No new safety signals were identified. ILUMYA is currently approved in the US and other countries for the treatment of moderate-to-severe plaque psoriasis in adults. Its use in psoriatic arthritis remains investigational and has not yet been evaluated by regulatory authorities. Detailed results from the INSPIRE studies will be presented at upcoming medical conferences and submitted for publication in peer-reviewed journals. Targeting IL-23 in chronic inflammatory pathways ILUMYA is a monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), thereby inhibiting inflammatory pathways associated with chronic autoimmune conditions. Common adverse reactions reported in previous studies include upper respiratory infections, injection-site reactions, and diarrhoea. The drug carries warnings related to hypersensitivity, infections, and tuberculosis risk. Psoriatic arthritis affects an estimated 2.4 million people in the United States. Approximately one-third of psoriasis patients may develop the joint condition, though many cases remain undiagnosed. Strategic pipeline strengthens global presence Sun Pharma is India's largest pharmaceutical company and one of the world's leading generic drug manufacturers. The company operates in over 100 countries and has a growing specialty portfolio in dermatology, ophthalmology, and onco-dermatology.

Sun Pharma announces top-line results of tildrakizumab 100 mg Phase 3 studies
Sun Pharma announces top-line results of tildrakizumab 100 mg Phase 3 studies

Business Standard

time3 hours ago

  • Business Standard

Sun Pharma announces top-line results of tildrakizumab 100 mg Phase 3 studies

For treatment of active psoriatic arthritis Sun Pharmaceutical Industries announced top-line results from two Phase 3 clinical studies evaluating the efficacy and safety of tildrakizumab 100 mg (ILUMYA) administered over 24 weeks for treatment of active psoriatic arthritis. Treatment with tildrakizumab 100 mg (ILUMYA) resulted in greater improvements in PsA signs and symptoms at Week 24 compared to treatment with placebo. Both the INSPIRE-1 and INSPIRE-2 studies achieved the primary endpoint, with a higher proportion of patients in the INSPIRE-1 and INSPIRE-2 studies treated with tildrakizumab achieving ACR20 responses at week 24, compared to those receiving placebo (p < 0.05). "We are excited to share that both the INSPIRE-1 and INSPIRE-2 clinical trials have successfully met their primary endpoints. These top-line results reinforce the therapeutic potential of ILUMYA as a treatment option for patients with active psoriatic arthritis. We extend our sincere gratitude to the patients, healthcare professionals and administrators whose contributions made the studies possible. We look forward to sharing the complete clinical data in the near future, said Marek Honczarenko, MD, PhD, Senior Vice President and Head of Global Specialty Development at Sun Pharma.

Weight loss drugs could improve polycystic ovary syndrome: All you need to know
Weight loss drugs could improve polycystic ovary syndrome: All you need to know

Time of India

time14 hours ago

  • Time of India

Weight loss drugs could improve polycystic ovary syndrome: All you need to know

Image credits: Getty Images According to the Endocrine Society, an estimated 5-6 million women of reproductive age in the U.S. are affected by PCOS, which is frequently underdiagnosed. Caused by high levels of testosterone and androgens, polycystic ovary syndrome leads to symptoms such as irregular periods, excess hair growth, acne, insulin resistance and more. It is one of the leading causes of infertility and is strongly linked to metabolic issues, leading to weight gain and hormonal imbalance. One would think a condition affecting such a huge number of women would have a treatment and medicine ready by now. However, when it comes to PCOS, a condition which also leads to other damaging conditions such as obesity and Type 2 diabetes, there's no standard treatment. Mostly, women opt for birth control, lifestyle changes and a diabetes drug, Metformin, which helps with some symptoms. However, now, a ray of light has come around in the form of popular weight loss drugs that are shockingly helping with improving PCOS. One of the many women who have experienced a positive result is Grace Hamilton, 27, who earlier had to battle problems like hair loss, heavy periods, inconsistent menstrual cycles, mental health problems and sudden weight loss. After getting diagnosed with PCOS, she tried birth control and lifestyle changes, only to see limited improvements. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas For Sale in Dubai Might Surprise You Villas in Dubai | Search Ads Get Info Undo It was in 2024 when Hamilton joined a trial examining the effects of GLP-1 drugs in PCOS patients. In October, she received her first dose of semaglutide, the active ingredient in Wegovy and Ozempic. The results, as she said to CNBC were almost immediate with resumed periods, hair regrowth and improvement in depression and anxiety. 'I'm so glad that I stuck with it because it was just clear as day that it was the missing link for me,' said Hamilton, adding that she also maintained a diet and exercise regimen. Are weight loss drugs really the answer? Image credits: Getty Images Some health experts see huge potential in GLP-1, particularly in their effect on improving weight loss and insulin sensitivity. 'The unmet need is massive,' said Dr. Melanie Cree, a pediatric endocrinologist at Children's Hospital Colorado, to CNBC. 'Primary therapies used for PCOS symptoms haven't changed in nearly 50 years.' Cree has been studying the effects of GLP-1 in adolescents with PCOS for more than 10 years. She previously studied the oral form of semaglutide and now has an ongoing clinical trial with the injectable version, which worked well for patients like Hamilton. Her trial began in 2023 with girls and women between the ages of 12-35 with obesity and PCOS who are on or off Metformin. Semaglutide was administered to the patients for 10 months to analyse their weight loss, metabolic changes and reproductive functions. The initial data included 11 women who completed the 10-month trial and were not on Metformin. 8 of these lost more than 10% of their body weight and saw a reduction in their hormone levels. Six of the 8 women even reported more regular periods. However, her study group is much smaller compared to the studies done on the popular weight loss drugs, and the results did not show similar effects on everyone. Here, the importance of conducting larger and longer trials on the same is important. This is because the potential for GLP-1 to cause relief in various PCOS symptoms remains. In previous studies, it has been found that in adults with PCOS, losing even 5% of body weight can improve insulin sensitivity. Thus, the body can respond better to insulin, and the pancreas doesn't need to pump out more insulin to keep the blood sugar in check. This will lower insulin levels, in turn lowering the production of testosterone and reducing symptoms of irregular period, acne and excess hair growth. Semaglutide not only improves insulin sensitivity but also reduces appetite by slowing how quickly the food leaves the stomach, prompting the pancreas to release insulin when the blood sugar is high and suppressing the release of a hormone that elevates blood sugar. Not only trials, a recent survey of 1700 people by the birth control app Natural Cycles, revealed that 64% of women with PCOS who took GLP-1 reported more predictable periods, and 20% reported that their bleeding days were shorter. Now, what is needed is a much larger research study on the subject to analyse its effects and see if it can be administered to all women with PCOS.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store